Urban et al1 recently developed the Academic Research Consortium for high bleeding risk (ARC-HBR) trade-off model. The new scores provide the predicted 1-year risk of nonperiprocedural major bleeding (Bleeding Academic Research Consortium [BARC] types 3-5 bleeding) and thrombotic events (myocardial infarction [MI] and/or definite or probable stent thrombosis [ST]) after coronary stenting in patients with HBR. In the development and validation cohorts, the C statistics were 0.68 and 0.74 for major bleeding and 0.68 and 0.74 for thrombotic events, respectively; C statistics in validation cohorts typically are lower than those observed in the development cohort. To support individual optimal antiplatelet therapy, bleeding and thrombotic risk scores should achieve helpful discrimination (C statistics, ≥0.60) in contemporary treatment strategies.2 We applied the scores to the GLOBAL LEADERS trial population.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Hara H, Ono M, Kawashima H, Onuma Y, Serruys PW. Trade-Off Between Bleeding and Thrombotic Risk in Patients With Academic Research Consortium for High Bleeding Risk. JAMA Cardiol. Published online June 02, 2021. doi:10.1001/jamacardio.2021.1558
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: